5:29 PM
Dec 13, 2013
 |  BC Extra  |  Company News

Group petitions FDA to overturn rescission of ANCHOR SPA

A group comprised mostly of Amarin investors sent a Citizen's Petition to FDA asking FDA Commissioner Margaret Hamburg to overturn the agency's October decision to rescind an SPA for the Phase III ANCHOR trial of Vascepa icosapent ethyl from Amarin Corp. plc (NASDAQ:AMRN). The biotech is seeking to expand Vascepa's...

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >